This paper presents the first case of asymptomatic IgG1 and IgG2 deficiency induced by carbamazepine (CBZ). The patient has remained asymptomatic since CBZ was started because IgM reduced only transiently, IgA decreased but remained within the normal range, and the specific antibodies to organisms having capsular polysaccharide antigens were not defective in this case. Analysis of membrane surface immunoglobulin (sIg) on B lymphocytes indicated that the maturation of B cells was defective from sIgM + cells to sIgG + cells. There have been no previous reports of IgG deficiency induced by CBZ due to this mechanism. Immunoglobulins should be carefully examined in patients treated with CBZ, particularly after its initiation.
INTRODUCTION
Antiepileptic drugs (AEDs) are known to induce immunological alterations. Phenytoin is the most common AED and has been demonstrated to induce various immunological abnormalities 1, 2 . Much less is known about the effect of carbamazepine (CBZ) on the immune system and it is often conflicting 2 . There have been only five cases reported with IgG deficiency induced by CBZ, in which all patients suffered from systemic illnesses such as infections or hypersensitivity syndrome 1, [3] [4] [5] [6] . This paper presents the first case of asymptomatic IgG1 and IgG2 deficiency due to a defect of B cell maturation induced by CBZ.
CASE REPORT
A 12-year-old boy suffered a tonic seizure for 2 minutes with shouting, deviation of his eyes and head to the left and flexion of the left arm. He had a similar episode 2 months later. Electroencephalogram showed right anterior temporal spikes. Brain magnetic resonance imaging did not demonstrate any abnormalities. Brain single photon emission computed tomography of 123 I-iodoamphetamine revealed slight hypoperfusion in the right hippocampus. He was diagnosed with localisation-related epilepsy and treated with CBZ (400 mg/44 kg body weight/day). His immunoglobulin levels measured by turbidimetric immunoassay 1 day before starting CBZ were within the normal range (Table 1) . One month later, IgG, IgA and IgM decreased but IgA and IgM remained within normal limits (Table 1) . Seven months later, IgG fell to almost half the value before CBZ therapy, IgA was in the lower end of the normal range, and IgM returned to the level before CBZ. IgG subclass measurement by enzyme-linked immunosorbent assay (ELISA) 7 revealed IgG1 and IgG2 deficiency (Table 1) . Specific IgG2 antibody to pneumococcal capsular polysaccharides (PCP) determined by ELISA 8 was normal (Table 1) . The white blood cell count was normal at 4.6 × 10 9 l −1 (52.8% neutrophil, 4.4% eosinophil, 0.1% basophil, 9.2% monocyte, 33.5% lymphocyte). Lymphocyte subpopulation studies demonstrated normal numbers of CD3+ (63.1%), 
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DISCUSSION
The effect of CBZ on IgG is controversial. IgG in epileptic patients on CBZ monotherapy for more than 6 months was revealed to be higher than that in healthy controls 9 or epileptic patients without AEDs 10 . However, other investigations showed that IgG did not differ among healthy controls, patients before and during CBZ treatment for a short-term 11, 12 or long-term 2, 13, 14 . With respect to the effect of CBZ on IgG subclasses, there is only one previous study demonstrating that IgG2 decreased from 3.2 to 2.47 g/l after 6 weeks of CBZ treatment but remained within the normal range for 12 months in epilepsy patients 15 . On the other hand, five isolated clinical cases of IgG deficiency have been described in association with CBZ therapy 1, [3] [4] [5] [6] . Two had a combined deficiency of IgG2 and IgA 1, 6 , and the other three had panhypogammaglobulinemia in which IgG subclasses were not measured [3] [4] [5] . There have been no previous reports describing a combined deficiency of IgG1 and IgG2 induced by CBZ. Two different physiological mechanisms have been demonstrated to induce IgG deficiency by CBZ: the absence of B cells 3, 4, 6 or elevated CD8+ cells 5 . Immunological investigations revealed that in vitro responses to mitogens and the number of T and B cells were normal in this case. The stages of B cell development are defined according to which sIg they bear; sIgM is expressed first on immature B cells, both sIgM and sIgD are coexpressed next on mature B cells and mature B cells differentiate to sIgG + and sIgA + cells with antigen stimulation. Increased sIgM + and sIgD + cells, low normal sIgA + cells and decreased sIgG + cells suggested that the maturation of B cells was defective from IgM + cells to IgG + cells in this case. There have been no previous reports describing IgG deficiency induced by CBZ due to this mechanism.
Despite IgG1 and IgG2 deficiency, this patient has been asymptomatic since CBZ was started. However, all of the previous five cases with IgG deficiency induced by CBZ developed an infection or recurrent infections with systemic symptoms such as fever, rash or hepatosplenomegaly 1, [3] [4] [5] [6] . In addition to IgG deficiency, they also had a deficiency of IgA 1, 6 or all classes of immunoglobulins except IgE [3] [4] [5] . On the other hand, IgM decreased only transiently and IgA decreased with CBZ therapy but remained within the normal range in this case. Anti-carbohydrate antibodies are considered to be restricted to the IgG2 subclass. In spite of a deficiency of total IgG2, specific IgG2 antibody to PCP was normal, indicating that the immune response to organisms having capsular polysaccharide antigens was not defective in this case. These differences might explain why this patient has been asymptomatic. However, if CBZ had been prescribed without interruption, immune abnormalities might have progressed further and infection might have developed in the future. Therefore, immunoglobulins should be carefully examined in patients treated with CBZ, particularly after its initiation.
